Breast Cancer

30-Second Snapshot

Two Classifications That Both Matter

Staging tells you how far the disease has spread. Receptor subtype tells you what drug will actually work. You need both, and they're graded independently of each other.

TNM stage

Clinical stageis assigned before surgery from exam, imaging, and biopsy. Pathologic stageis assigned after surgery once you have actual resection and surgical node data. They can differ, and pathologic stage is the more accurate of the two.

Receptor subtype - the variable that actually picks the drug

Pathophysiology - Why the Drugs Work

Three signaling pathways drive breast cancer growth, and nearly every drug on this page blocks one of them.

Pathway 1: estrogen receptor signaling (the ER+ pathway)

Estradiol binds the estrogen receptor, which then binds DNA and drives gene transcription and cell proliferation. In ER+ tumors this pathway is switched on constantly, driving unchecked cell division. Every hormone-pathway drug interrupts it at a different point:

Why SERMs are tissue-selective:tamoxifen is an antagonist in breast tissue (blocks proliferation, the goal) but a partial agonistin bone (preserves density, a bonus) and in the endometrium (promotes hyperplasia, a liability that raises endometrial cancer risk). Same drug, same receptor, opposite effect depending on the tissue. That's the whole premise behind the term SERM: what's good for the bone may not be good for the breast.

Pathway 2: HER2 signaling

HER2 is a growth-signaling receptor. When it's overexpressed, in about 15–20% of tumors, it drives aggressive proliferation independent of hormones. HER2-targeted antibodies (trastuzumab, pertuzumab) bind the receptor and block its downstream signaling; antibody-drug conjugates (T-DM1, fam-trastuzumab deruxtecan) use the antibody as a delivery vehicle to smuggle cytotoxic chemo directly into HER2-expressing cells; small-molecule TKIs (neratinib, tucatinib, lapatinib) block the intracellular kinase domain instead.

Pathway 3: cell cycle control (CDK4/6)

Cyclin-dependent kinases 4 and 6 drive the cell from G1 into S phase. In HR+ tumors, estrogen signaling upregulates cyclin D, which activates CDK4/6, which inactivates the retinoblastoma protein and releases the brake on the cell cycle. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) block that step directly, which is exactly why they're combined with an AI or fulvestrant rather than used alone: you're hitting the pathway at two points at once.

No target: triple negative disease

Without ER, PR, or HER2 to exploit, triple negative tumors get treated the way cancer was treated before targeted therapy existed: cytotoxic chemotherapy that kills any rapidly dividing cell. Newer options exploit other vulnerabilities: immunotherapy for PD-L1 expressing tumors, PARP inhibitors for BRCA-mutated DNA repair defects, and antibody-drug conjugates like sacituzumab govitecan that deliver chemo via a surface antigen instead of a hormone receptor.

Clinical Presentation

A painless, palpable lumpis the most common initial sign. The classic malignant mass is solitary, unilateral, solid, hard, irregular, and nonmobile (it doesn't slide around under your fingers the way a fibroadenoma does). Nipple changes are less common. More advanced local disease shows skin edema, redness, warmth, and induration, the picture of inflammatory breast cancer.

Increasingly, breast cancer is caught before any of this happens, on a screening mammogram in a completely asymptomatic woman. That early catch is the whole point of screening.

Diagnosis & Workup

Workup starts with history, breast exam, and 3D mammography, sometimes supplemented with ultrasound, MRI, digital mammography, or tomosynthesis. Biopsyis indicated for any mammographic abnormality suggesting malignancy or any palpable mass on exam. Most breast carcinomas are adenocarcinomas, subclassified as ductal or lobular.

What the pathology report needs to tell you

• Tumor size and number of involved axillary lymph nodes,the two independent factors that most influence recurrence risk.
• Histologic subtype, nuclear/histologic grade, lymphovascular invasion, proliferation indices,additional prognostic detail.
• ER and PR status,weak prognostic markers but the whole reason to give endocrine therapy.
• HER2 status,the reason to give HER2-targeted therapy. Overexpression in 15–20% correlates with more aggressive disease if untreated.
• Genomic/multigene expression assays,used as decision-support tools to help decide who actually needs adjuvant chemo on top of endocrine therapy.

Curative Treatment - Stage I to III

Goal is cure. Adjuvant systemic therapy (given after local therapy) eradicates micrometastatic disease you can't see on imaging. Neoadjuvant therapy (given before surgery) is standard for locally advanced (Stage III) disease, shrinking the tumor and sometimes allowing breast-conserving surgery instead of mastectomy.

Local-regional therapy first

• Surgery alonecures most in situ disease, 70–80% of Stage I, and about half of Stage II. It's more effective the earlier you catch it.
• Breast-conserving therapy (BCT):partial mastectomy plus axillary node evaluation plus radiation. Cosmetic and survival outcomes are comparable to full mastectomy.
• Radiationafter BCT runs 3–5 weeks to the whole breast, eradicating residual disease. Reddening/erythema with later shrinkage of breast tissue are the main short-term complications.
• Mastectomyis indicated for multiple cancer sites within the breast or inability to achieve negative margins with BCT.
• Sentinel lymph node biopsyis the less invasive alternative to full axillary dissection for nodal staging.

Adjuvant / neoadjuvant chemotherapy

Anthracyclines (doxorubicin, epirubicin) and taxanes (paclitaxel, docetaxel) are the backboneof modern adjuvant chemo, usually combined rather than given alone since combination regimens outperform single agents. Chemo should start within 12 weeksof surgery, and total duration is usually 12–24 weeks depending on the regimen.

HER2-positive early-stage disease

Trastuzumab,an anti-HER2 monoclonal antibody, combined with or given sequentially after adjuvant chemo, cuts recurrence risk by up to 50% in early HER2+ disease. The benefit is well established even though the exact best chemo backbone, sequence, and duration are still debated across trials.

Pertuzumabadds to trastuzumab plus chemo specifically in the neoadjuvant setting for HER2+ disease. Neratinib(240 mg PO daily for 1 year), an oral TKI hitting EGFR, HER2, and HER4, is used for extended adjuvant therapy aftera patient finishes their year of trastuzumab. Its main toxicities are diarrhea, nausea, fatigue, and vomiting, all GI-heavy. Ado-trastuzumab emtansine (T-DM1)steps in for the adjuvant setting when a patient still has residual disease found at surgery after neoadjuvant therapy, meaning the first regimen didn't fully clear the tumor. Its signature toxicities are peripheral neuropathy, thrombocytopenia, and liver dysfunction.

Endocrine Therapy - Adjuvant and Risk Reduction

For HR+ disease, hormone-pathway therapy is the backbone of both adjuvant treatment and, in high-risk women who don't yet have cancer, prevention. Menopausal status is the single biggest variable in picking the agent.

Risk reduction in high-risk, cancer-free women

• SERMs(tamoxifen, raloxifene) for 5 years reduce invasive and noninvasive breast cancer risk by about 50%in high-risk women. Tradeoff: tamoxifen raises endometrial cancer risk, and both raise VTE risk.
• AIs(exemestane, anastrozole) give a similar reduction in contralateral primary breast cancer in high-risk, postmenopausalwomen.
• Guidelines recommend a SERM or AI for risk reduction specifically in postmenopausal women at high risk.

Adjuvant endocrine therapy by menopausal status

Tamoxifen 20 mg daily, started after chemo finishes and continued 5–10 years, reduces both recurrence and mortality. It's generally well tolerated (hot flashes, vaginal discharge) and actually reduceship, radius, and spine fracture risk through its bone-agonist effect. The tradeoffs are increased stroke, PE, DVT, and endometrial cancer risk, particularly at age 50 and older.

Metastatic Breast Cancer - Stage IV

The goal flips entirely here: palliation, not cure.Optimizing benefit while minimizing toxicity and preserving quality of life are the actual therapeutic endpoints, not eradication. Treatment choice depends on extent of disease and, most importantly, the HER2, ER, and PR statusof the primary or metastatic tissue (rebiopsy at progression is common because receptor status can change over time).

For bone metastases, add a bone-modifying agent(pamidronate, zoledronic acid, or denosumab) to reduce skeletal-related events (fractures, spinal cord compression, pain) and the need for surgery or radiation to bone.

HR-positive MBC: endocrine-based, with a targeted agent bolted on

Endocrine therapy (an AI, tamoxifen/toremifene, or fulvestrant) combined with a targeted agent is preferred first-line whenever feasible, this combination approach overcomes both de novo and acquired endocrine resistance better than endocrine therapy alone. No single endocrine agent has clearly superior survival, so choice comes down to mechanism, toxicity, and patient preference, exceptwhen the cancer recurs during or within one year of adjuvant therapy with that same drug class, in which case you switch classes.

Fulvestrant itself (an IM SERD) is approved second-line in postmenopausal HR+ MBC, alone or combined with a targeted agent; with ovarian suppression or ablation it's appropriate premenopausally too. Its own toxicities are injection-site reactions, hot flashes, asthenia, and headache. As with tamoxifen, tumor flare or hypercalcemia occurs in roughly 5% of MBC patients on a SERM.

HER2-positive MBC

First line:pertuzumab plus trastuzumab plus a taxane, for patients who haven't already had pertuzumab in the neoadjuvant or adjuvant setting. Second line:ado-trastuzumab emtansine (T-DM1) after progression or intolerance to first line. Third line and beyondis genuinely unsettled, choice depends on brain metastases, organ function, and residual toxicity from prior lines. HER2-targeted agents available in the US: trastuzumab, pertuzumab, T-DM1, fam-trastuzumab deruxtecan, margetuximab, lapatinib, neratinib, tucatinib. Every one of them carries some degree of cardiotoxicity.

Triple negative / HER2-negative MBC: chemotherapy is the backbone

Chemo is first-line for hormone receptor-negative tumors, triple negative tumors, and anyone who's failed endocrine/targeted therapy. Combination chemo produces an objective response in 47–55%of chemo-naive patients, but sequential single agents are usually preferredover combinations because efficacy is often similar and toxicity is lower. Combination regimens are reserved for rapidly progressive disease, life-threatening visceral involvement, or when a fast symptom response is needed.

Anthracyclines and taxanes give the best first-line response rates in MBC (up to 50%). After a patient has already had both, single-agent capecitabine, vinorelbine, or gemcitabine only pull 20–25% response rates. Most responses are partial, lasting a median of 3–15 months, with median overall survival of 10–33 months; continue whatever regimen is working until progression or intolerable toxicity.

Radiation in MBC

Used for painful bone metastases or localized refractory disease (brain, spinal cord, eye, orbit). Pain relief from bone-met radiation happens in about 90%of patients, one of the most reliably effective palliative interventions in oncology.

Key Agent Dosing

Focused on the oral/self-administered endocrine and targeted agents students actually get asked about. IV chemo regimens are dosed by protocol (see tables above) and by BSA/AUC, not fixed daily doses.

Class-by-Class Detail

Toxicity, Interactions & Special Populations

Hormone replacement therapy and breast cancer risk - the WHI nuance

This gets tested and it's commonly oversimplified to "HRT causes breast cancer." The truth is more specific: in the Women's Health Initiative, the combined estrogen plus progestin arm increased breast cancer risk, while the estrogen-alone arm (in women without a uterus) actually reduced it. The progestin, specifically medroxyprogesterone, is the driver of the increased risk, not estrogen by itself. In absolute terms: baseline risk was about 23 cases per 1,000, with combined HRT adding roughly 4 more cases per 1,000 in an otherwise average-risk woman, more if she has other underlying risk factors.

A tissue-selective estrogen complex (bazedoxifene plus conjugated estrogen) was designed around the theory that pairing an anti-breast-tissue SERM with estrogen would cut breast cancer risk versus estrogen alone. That theoretical risk reduction hasn't actually been demonstratedin practice, so it still carries the same precautions as standard HRT, worth knowing since it's sometimes marketed as the "safer" option.

Cardiotoxicity risk stacking

Anthracyclines and HER2-targeted agents are each independently cardiotoxic, and the risk compounds when they're combined. Symptomatic HF occurs in 0.5–4% of patients on anthracycline-based trastuzumab regimens, versus a much lower rate with non-anthracycline HER2 regimens like TCH. Baseline and serial cardiac function assessment, usually echo or MUGA, is standard before and during HER2-targeted therapy for exactly this reason.

Other agent-specific watch points

• Alpelisib:monitor fasting glucose closely, hyperglycemia including DKA can occur, plus rash and diarrhea.
• Neratinib:near-universal diarrhea; antidiarrheal prophylaxis is often started with the first dose, not after symptoms begin.
• T-DM1:peripheral neuropathy, thrombocytopenia, hepatotoxicity.
• CDK4/6 inhibitors:avoid concomitant strong CYP3A4 inhibitors/inducers across the whole class; don't split the tablets.
• Fulvestrant, tamoxifen (MBC setting):tumor flare or hypercalcemia in roughly 5% of patients starting therapy.

Monitoring - What, When, Why

Patient Counseling - What You'll Actually Say

High-Yield Recall Sheet